2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1119

Genetic Signatures from RNA Sequencing of Pediatric Localized Scleroderma (LS) Skin

Systemic Sclerosis and Related Disorders – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1135

Genome-Wide Meta-Analysis Identified Two Novel Variants Associated with Hallux Valgus

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1714

Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research

Systemic Lupus Erythematosus – Clinical Poster – ARHP

9:00AM-11:00AM: Abstract Number: 1386

Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1147

Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1126

Gout and Chronic Pain in Older Adults: A Medicare Claims Study

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1298

Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 990

Guanylate Binding Protein 5 (GBP5) Inhibits Rheumatoid Arthritis Synovial Fibroblast Mediated Inflammation and Tissue Destruction

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1251

Guideline Adherence for Perioperative Use of Immunosuppressive Medications in Patients with Rheumatologic Disease

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1676

Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1384

Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1417

Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

9:00AM-11:00AM: Abstract Number: 1224

High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1719

High-Throughput Quantitative Histology in Systemic Sclerosis Skin Disease Using Computer Vision

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1280

Higher Body Fat Percentage in Non-Obese Late-Onset Gout Patients

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].